Furthermore, DADS treatment not only significantly decreased glucose consumption, intracellular G6P levels and G6PD activities, but also significantly mitigated or abrogated the POU2F1 over-expression-increased glucose consumption, intracellular G6P levels and G6PD activities in CRC HCT116 cells. This evidence concerns the gene G6PD and colorectal carcinoma.